Altrius Capital Management Inc Raises Stock Position in Pfizer Inc. (NYSE:PFE)

Altrius Capital Management Inc grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 2.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 84,064 shares of the biopharmaceutical company’s stock after buying an additional 1,842 shares during the quarter. Altrius Capital Management Inc’s holdings in Pfizer were worth $3,083,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Bank Julius Baer & Co. Ltd Zurich boosted its stake in shares of Pfizer by 98,197.9% during the 2nd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,948,438,709 shares of the biopharmaceutical company’s stock worth $71,468,732,000 after purchasing an additional 1,946,456,532 shares during the period. BlackRock Inc. boosted its position in shares of Pfizer by 0.6% during the first quarter. BlackRock Inc. now owns 445,384,893 shares of the biopharmaceutical company’s stock valued at $18,171,704,000 after buying an additional 2,516,132 shares during the period. Wellington Management Group LLP grew its stake in shares of Pfizer by 9.8% during the first quarter. Wellington Management Group LLP now owns 218,931,933 shares of the biopharmaceutical company’s stock valued at $8,932,423,000 after buying an additional 19,602,359 shares during the last quarter. Moneta Group Investment Advisors LLC raised its holdings in shares of Pfizer by 89,592.7% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after buying an additional 160,963,976 shares during the period. Finally, Geode Capital Management LLC raised its holdings in shares of Pfizer by 0.5% in the first quarter. Geode Capital Management LLC now owns 109,852,779 shares of the biopharmaceutical company’s stock worth $4,472,433,000 after buying an additional 577,201 shares during the period. Institutional investors own 68.05% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the topic of several research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $75.00 price objective on shares of Pfizer in a research report on Monday, October 2nd. UBS Group restated a “neutral” rating and issued a $34.00 price target (down from $36.00) on shares of Pfizer in a report on Friday, October 20th. Barclays decreased their price objective on shares of Pfizer from $35.00 to $34.00 and set an “equal weight” rating for the company in a report on Wednesday, November 1st. Citigroup dropped their target price on shares of Pfizer from $42.00 to $35.00 and set a “neutral” rating on the stock in a research note on Monday, October 16th. Finally, Jefferies Financial Group raised shares of Pfizer from a “hold” rating to a “buy” rating and lifted their price target for the company from $38.00 to $39.00 in a research note on Monday, October 16th. Twelve research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, Pfizer presently has an average rating of “Hold” and a consensus target price of $42.50.

Pfizer Stock Down 0.0 %

PFE traded down $0.01 on Monday, hitting $29.91. The company had a trading volume of 7,009,113 shares, compared to its average volume of 25,462,936. The stock has a market capitalization of $168.88 billion, a price-to-earnings ratio of 16.35, a P/E/G ratio of 1.91 and a beta of 0.63. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.05 and a current ratio of 2.38. The stock has a fifty day moving average price of $31.97 and a 200-day moving average price of $35.23. Pfizer Inc. has a 12-month low of $28.93 and a 12-month high of $54.93.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 31st. The biopharmaceutical company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.15. Pfizer had a net margin of 15.30% and a return on equity of 16.72%. The company had revenue of $13.23 billion during the quarter, compared to analysts’ expectations of $13.77 billion. Analysts predict that Pfizer Inc. will post 1.56 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 4th. Shareholders of record on Friday, November 10th will be issued a $0.41 dividend. This represents a $1.64 annualized dividend and a yield of 5.48%. The ex-dividend date of this dividend is Thursday, November 9th. Pfizer’s dividend payout ratio is presently 89.62%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.